Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.70 |
| ▸ | ACHE | P22303 | 3/20 | 0.70 |
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.54 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CCR1 | P32246 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12210458 | 0.81 | BCHE (0.87) | BCHEACHECYP1A2KMT2ACCR1 | |
| SCHEMBL11883617 | 0.80 | SMN1; SMN2 (0.50) | BCHEACHEFERMT2 | |
| Hydrochloric Acid SCHEMBL29684136 | 0.78 | CYP1A2 (0.54) | BCHEACHEKMT5BKMT5CCYP1A2 | |
| SCHEMBL19556600 | 0.74 | NR4A2 (0.51) | BCHEACHEKMT5BKMT5CCYP1A2 | |
| SCHEMBL7206080 | 0.73 | KMT5B (0.79) | BCHEACHEKMT5BKMT5CCYP1A2 | |
| SCHEMBL7206069 | 0.73 | KMT5B (0.79) | BCHEACHEKMT5BKMT5CCYP1A2 | |
| SCHEMBL6870026 | 0.73 | KMT5B (0.60) | BCHEACHEKMT5BKMT5CKMT2A | |
| SCHEMBL6872121 | 0.73 | KMT5B (0.89) | KMT5BKMT5CCYP1A2MAPTKMT2A | |
| SCHEMBL7207215 | 0.73 | KMT5B (0.89) | KMT5BKMT5CCYP1A2MAPTKMT2A | |
| SCHEMBL6872111 | 0.73 | KMT5B (0.89) | KMT5BKMT5CCYP1A2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481543-B2 | Compounds for treating parasitic disease | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110251209-A1 | COMPOUNDS FOR TREATING PARASITIC DISEASE | OREGON HEALTH & SCIENCE UNIVERSITY | 2011-10-13 | — | — | US | disclosed |
| WO-2010059633-A2 | COMPOUNDS FOR TREATING PARASITIC DISEASE | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251209-A1 | COMPOUNDS FOR TREATING PARASITIC DISEASE | EPX, CFTR, TERT | BCHE 493/4885ACHE 1932/4885KMT5B 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.